Bachem refocuses after financing and management moves, shares track Swiss biotech peers
26.06.2026 - 14:12:15 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 14:11.
Bachem Holding AG (CH0012530207) remains in focus on the SIX Swiss Exchange after a string of June corporate decisions. The Swiss peptide producer agreed a sizeable new credit line and announced a senior management change, according to recent company and market reports.
New UBS credit facility in June
On 9 June 2026 Bachem disclosed a committed credit facility of 500 million Swiss francs arranged with UBS, replacing and expanding existing bank lines to support its capacity expansion plans. An aktiencheck.de summary of the UBS facility The agreement gives the company additional financial flexibility for new production plants and technology investments.
According to Swiss financial portals, the facility runs over multiple years and is intended to back Bachem’s long-term growth strategy in peptides and oligonucleotides. A finanzen.net report highlights the expansion focus This move follows a period of elevated capital expenditure as the group builds out additional manufacturing capacity at several sites.
Management change in commercial leadership
Earlier in June, Bachem announced that Chief Commercial Officer Torsten Wöhr will leave the company, prompting a reallocation of commercial responsibilities within the executive team. Finanzen.net reported on the CCO departure The change affects the leadership of sales and customer relations for both generic and contract development business.
Swiss investor commentary notes that Bachem, part of the SPI and a peer to groups such as Lonza in contract development, is adjusting its commercial setup while keeping its strategic focus on complex peptides. Finanzen100 lists Bachem in the STOXX Europe 600 Health Care The combination of new financing and leadership change marks a concentrated phase of operational fine-tuning in June.
Background and price data on Bachem
Further news, historical performance and regulatory disclosures on the Bachem shares can be found in the dedicated topic section and on the company’s Investor Relations site.
Peptide manufacturing as core business
Bachem generates its revenue primarily by developing and manufacturing peptide-based active pharmaceutical ingredients and related products for pharmaceutical and biotech clients. The portfolio ranges from standard generic peptides to complex custom sequences for clinical and commercial use.
Where the shares trade today
The Bachem shares (CH0012530207) trade on the SIX Swiss Exchange under the ticker BANB at 64.50 Swiss francs as of 2026-06-26, 11:55.
Key data on the Bachem shares
- Company: Bachem Holding AG
- ISIN: CH0012530207
- WKN: 904476
- Ticker: BANB
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-26, 11:55): 64.50 CHF
- Market cap: 4.4 billion CHF (as of 2026-06-26)
- Sector / industry: Health Care / Biotechnology
- Index membership: SPI, STOXX Europe 600 Health Care
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial advice. All data are based on publicly available sources deemed reliable but without any guarantee of accuracy or completeness.
